The fate of the Affordable Care Act is shaping up to be the hottest healthcare issue publicly in 2017, but investors are watching drug pricing trends and M&A activity just as closely, says Goldman Sachs Research’s Jami Rubin. She explains why we’re likely to see a pickup in deals in a constrained pricing environment.